Our focus is on revolutionizing the pharmaceutical supply chain, ensuring each product from production to patient is genuine, safe, and transparent. By leveraging blockchain technology, we offer an unmatched level of security and transparency, critical in combating the global issue of counterfeit pharmaceuticals.
Blockchain enabels real-time visibility of pharmaceuticals from manufacture to delivery, ensuring authenticity, safety and provenance.
Through immutable records, blockchain technology aids in identifying and preventing the distribution of counterfeit pharmaceutical products.
Smart contracts automate and secure the flow of information, ensuring continuous, real-time tracking of pharmaceuticals.
Blockchain also facilitates trusted peer-to-peer transactions, eliminating intermediaries and enhancing the integrity of items in transit.
Enables precise tracking of pharmaceuticals, including their handling and storage conditions, to ensure quality and safety from production to patient.
Establishes a framework for effective communication and collaboration among all parties involved in the pharmaceutical supply chain, fostering trust and reducing risk.
Provides the agility to respond swiftly to disruptions, maintaining the integrity of the supply chain without significant cost increases.
Ensures adherence to global standards and regulatory requirements, guaranteeing the legal distribution and sale of pharmaceutical products.
The Batch Block initiative is deeply engaged in addressing the complex challenges faced by the pharmaceutical supply chain. Collaborating closely with experts from the University of Surrey, we are pioneering research and developing solutions to overcome these hurdles, ensuring the safety and reliability of pharmaceutical products. This collaboration underscores our commitment to leveraging academic insights and cutting-edge technology to build a safer, more transparent supply chain for pharmaceuticals.
These databases however, still rely on siloed data sources and exchanges of information via two-way interactions, suggesting that the marketplace lacks a technology solution for the problem.
Head of Surrey University Department of Veterinary Epidemiology and Public Health